Trials / Recruiting
RecruitingNCT06090539
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 308 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986458 | Specified dose on specified days. |
| DRUG | Rituximab | Specified dose on specified days. |
| DRUG | Glofitamab/Obinutuzumab | Specified dose on specified days |
| DRUG | Mosunetuzumab | Specified dose on specified days |
Timeline
- Start date
- 2023-12-29
- Primary completion
- 2027-10-28
- Completion
- 2028-10-28
- First posted
- 2023-10-19
- Last updated
- 2026-04-14
Locations
65 sites across 13 countries: United States, Chile, China, France, Germany, Greece, Italy, Japan, Netherlands, South Korea, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06090539. Inclusion in this directory is not an endorsement.